{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Inpatient admission under neurology\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Requires urgent MRI and lumbar puncture for diagnosis Needs supervised high-dose intravenous steroids and monitoring for adverse effects Gait ataxia increases falls risk requiring supervised mobility assessment\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Acute optic neuritis and cerebellar relapse causing functional impairment High-dose steroids accelerate neurological recovery in inflammatory demyelination No focal signs suggesting active infection or alternative steroid contraindication on current data\n\n*   **Treatment:** Oral prednisolone taper following IV methylprednisolone\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Only required after completion of IV course to reduce rebound symptoms Dose and duration should be tailored once response and side effects to IV therapy are seen\n\n*   **Treatment:** Proton pump inhibitor for gastroprotection\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** High-dose corticosteroids increase risk of gastrointestinal irritation and ulceration Patient will likely receive several days of systemic steroids\n\n*   **Treatment:** Thromboprophylaxis with low-molecular-weight heparin and compression stockings while inpatient\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Reduced mobility from ataxia increases venous thromboembolism risk High-dose steroids further increase thrombotic risk\n\n*   **Treatment:** Physiotherapy and occupational therapy for gait and balance rehabilitation\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Cerebellar ataxia and unstable tandem gait predispose to falls Early rehabilitation improves functional outcomes and safety at home\n\n*   **Treatment:** Initiation of disease-modifying therapy for multiple sclerosis (agent chosen per risk profile and guidelines)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Requires confirmation of MS diagnosis with MRI and CSF findings Baseline screening (blood tests, infection screen, pregnancy status where relevant) must precede therapy Choice of agent (e.g., ocrelizumab, natalizumab, fingolimod, interferon-beta) should follow multidisciplinary discussion and patient counselling\n\n*   **Treatment:** Vitamin D level assessment and supplementation if deficient\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Low vitamin D is associated with increased MS disease activity Dose should be determined after laboratory confirmation to avoid hypervitaminosis D\n\n*   **Treatment:** Therapeutic plasma exchange\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reserved for steroid-refractory severe relapse or if NMOSD/MOG-associated disease is confirmed or strongly suspected Invasive therapy with significant risks; only indicated if inadequate improvement after steroid course\n\n*   **Treatment:** Patient education and counselling, including driving and employment advice\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Diagnosis or strong suspicion of demyelinating disease has major psychosocial impact Visual and gait impairment may affect driving safety and occupational activities, requiring early guidance\n\n\ntreatments = [{\"treatment\": \"Inpatient admission under neurology\", \"timing\": \"Start Now\", \"reasons\": [\"Requires urgent MRI and lumbar puncture for diagnosis\", \"Needs supervised high-dose intravenous steroids and monitoring for adverse effects\", \"Gait ataxia increases falls risk requiring supervised mobility assessment\"]}, {\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Acute optic neuritis and cerebellar relapse causing functional impairment\", \"High-dose steroids accelerate neurological recovery in inflammatory demyelination\", \"No focal signs suggesting active infection or alternative steroid contraindication on current data\"]}, {\"treatment\": \"Oral prednisolone taper following IV methylprednisolone\", \"timing\": \"Delay\", \"reasons\": [\"Only required after completion of IV course to reduce rebound symptoms\", \"Dose and duration should be tailored once response and side effects to IV therapy are seen\"]}, {\"treatment\": \"Proton pump inhibitor for gastroprotection\", \"timing\": \"Start Now\", \"reasons\": [\"High-dose corticosteroids increase risk of gastrointestinal irritation and ulceration\", \"Patient will likely receive several days of systemic steroids\"]}, {\"treatment\": \"Thromboprophylaxis with low-molecular-weight heparin and compression stockings while inpatient\", \"timing\": \"Start Now\", \"reasons\": [\"Reduced mobility from ataxia increases venous thromboembolism risk\", \"High-dose steroids further increase thrombotic risk\"]}, {\"treatment\": \"Physiotherapy and occupational therapy for gait and balance rehabilitation\", \"timing\": \"Start Now\", \"reasons\": [\"Cerebellar ataxia and unstable tandem gait predispose to falls\", \"Early rehabilitation improves functional outcomes and safety at home\"]}, {\"treatment\": \"Initiation of disease-modifying therapy for multiple sclerosis (agent chosen per risk profile and guidelines)\", \"timing\": \"Delay\", \"reasons\": [\"Requires confirmation of MS diagnosis with MRI and CSF findings\", \"Baseline screening (blood tests, infection screen, pregnancy status where relevant) must precede therapy\", \"Choice of agent (e.g., ocrelizumab, natalizumab, fingolimod, interferon-beta) should follow multidisciplinary discussion and patient counselling\"]}, {\"treatment\": \"Vitamin D level assessment and supplementation if deficient\", \"timing\": \"Delay\", \"reasons\": [\"Low vitamin D is associated with increased MS disease activity\", \"Dose should be determined after laboratory confirmation to avoid hypervitaminosis D\"]}, {\"treatment\": \"Therapeutic plasma exchange\", \"timing\": \"Delay\", \"reasons\": [\"Reserved for steroid-refractory severe relapse or if NMOSD/MOG-associated disease is confirmed or strongly suspected\", \"Invasive therapy with significant risks; only indicated if inadequate improvement after steroid course\"]}, {\"treatment\": \"Patient education and counselling, including driving and employment advice\", \"timing\": \"Start Now\", \"reasons\": [\"Diagnosis or strong suspicion of demyelinating disease has major psychosocial impact\", \"Visual and gait impairment may affect driving safety and occupational activities, requiring early guidance\"]}]"
}